Skip to main content
GLP-1 / MetabolicVerified

Pemvidutide

ALT-801

A dual GLP-1 and glucagon receptor agonist studied in trials for weight management and for metabolic dysfunction-associated steatotic liver disease. The glucagon component is included for its effect on hepatic fat rather than on appetite alone. Not approved.

Pemvidutide
Category
GLP-1 / Metabolic
Half-life
Not established in a public source
Common vial
Varies
Regulatory
Investigational

Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.

01

Regulatory status

Investigational

This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.

A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.

02

Half-life

Not established in a public source. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.

03

Storage & handling

Investigational; no approved label defines handling.

04

References

  • J Hepatology 2025: effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD

Read the source

Common questions

Pemvidutide, answered plainly.

01What is Pemvidutide?+

A dual GLP-1 and glucagon receptor agonist studied in trials for weight management and for metabolic dysfunction-associated steatotic liver disease. The glucagon component is included for its effect on hepatic fat rather than on appetite alone. Not approved. It is also referred to as ALT-801. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.

02Is Pemvidutide FDA approved?+

Investigational. This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.

03What is the half-life of Pemvidutide?+

Not established in a public source. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.

04How is Pemvidutide stored and handled?+

Investigational; no approved label defines handling. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.

Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.